Splenectomy for Primary Immune-Mediated Anemia (PIMA)

Efficacy of Splenectomy in Immune-Mediated Conditions

Splenectomy provides high initial response rates (approximately 85%) in immune thrombocytopenia (ITP), which shares immunological mechanisms with PIMA 2
Long-term sustained responses are seen in about 60-65% of patients with ITP following splenectomy 2
However, up to 30% of responders will relapse within 10 years after splenectomy, most commonly within the first 2 years 2, 1

Corticosteroids are the recommended initial treatment for immune-mediated conditions like PIMA, with longer courses preferred over shorter courses 3
For patients who have failed corticosteroid therapy, splenectomy can be considered as a second-line therapy 3
Before considering splenectomy, other second-line options, such as rituximab or thrombopoietin receptor agonists (TPO-RAs), should be evaluated 4

Surgical complications occur in approximately 10% of patients within 30 days following splenectomy, even with laparoscopic techniques 2, 1
Long-term risks of splenectomy include increased risk of infections (3-fold higher risk of septicemia), thromboembolic events (4.5-fold increased risk of pulmonary embolism), and potential increased risk of certain malignancies 2, 1
Lifelong management to prevent sepsis is required, including vaccinations and prophylactic antibiotics 2

Regular follow-up is essential as relapse can occur, particularly within the first 2 years 1
For patients who relapse or fail to respond to splenectomy, additional therapies such as rituximab or TPO-RAs may be considered 3, 4